Ann: AstraZeneca to use new ResApp software in study - Revised, page-12

There is one word in this announcement that I believe is critical going forward.

“To have our technology licensed by a company of AstraZeneca’s reputation is a major achievement and provides significant validation of ResApp’s products and capability. They have some of the world’s leading scientists and researchers running clinical trials and treatment programs and we are confident that their input will enhance our technology for future commercial applications and deployments."


Validation of our technology is key. After successive failures and delays, many in the market still believe our technology is a gimmick.

Validation of our technology will eventually change the opinion of the market and result in a significantl re-rate of our sp.